The present study aimed to evaluate the effects of quetiapine (Seroquel), an antagonist of GABA-B receptors, on the behavioral and autonomic responses of pre- and post-ictal individuals.Seroquelis a non-selective GABA-B receptor antagonist that is primarily used to treat mental disorders in schizophrenia, bipolar disorder, and major depressive disorder. The present study sought to determine whether it could influence the clinical features of the pre- and post-ictal patients. A total of 103 patients with schizophrenia and bipolar I disorder were recruited from the psychiatric clinic of Saitama Hospital and Saitama University (SAU), Saitama, Japan. Before and after drug administration, a self-administered validated questionnaire (SAP) was used to evaluate the patients' behavioral and autonomic responses to the stimuli. Serotonin, noradrenaline, and dopamine concentrations in the serotonergic and dopaminergic neurons of the pre- and post-ictal patients were analyzed. The efficacy of quetiapine was evaluated using the Hamilton Depression Rating Scale (HAM-DRS) at pre- and post-administration, and the autonomic responses were assessed at pre- and post-administration. Serotonin, noradrenaline, and dopamine concentrations were also measured at pre- and post-administration. In a subset of patients, the mean number of adverse events was significantly lower in the pre-administration group. In contrast, there were no differences in the incidence of major adverse events between the pre- and post-administration groups. The overall efficacy of quetiapine was not significantly different from that of placebo. The results of the present study support the hypothesis that quetiapine can significantly reduce the adverse reactions associated with the use of psychotropic medications in patients with schizophrenia, bipolar disorder, and major depressive disorder.
Citation:Kumar S, K. S. K. et al. (2019) Effects of quetiapine on the clinical features of pre- and post-ictal patients (Seroquel) (American Psychiatric Association;Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, text revision, text revision C-II) (Seroquel). PLoS ONE 11(7): e868303. https://doi.org/10.1371/journal.pone.00868303
Editor:Takashi Yasuhara, Kyushu University Graduate School of Medicine, UNITED STATES
Received:December 4, 2019;Accepted:April 26, 2020;Published:May 3, 2020
Copyright:© 2020 Kumar et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability:All relevant data are within the paper and its files.
Funding:This work was supported by a grant from the Japan Education Research Foundation (No. 16-10-00133), and is the subject of an Open Access Publication to the National Research Foundation (No. 17-63110). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests:The authors have declared that no competing interests exist.
Quetiapine is a non-selective antidepressant of the serotonin and noradrenaline receptor antagonism class of antidepressant drugs. Its mechanism of action is related to a reduction of serotonin and noradrenaline receptors, thus inhibiting the reuptake of these neurotransmitters by the presynaptic neurons. Its use has become the first line of treatment of schizophrenia and bipolar disorder. Its main mechanism is to reduce the inhibitory effects of serotonin on the reuptake of noradrenaline by the presynaptic neurons. Serotonin reuptake inhibitors have been shown to cause sedation. The main adverse effects are somnolence and weight gain. However, they are associated with a very small risk of death. It is important to note that quetiapine is a first-line therapy for schizophrenia and bipolar disorder but can also be used for other conditions, including post-traumatic stress disorder, major depression, and anxiety disorders.
A few years ago, I was in a situation that was very similar to what I had seen with my first prescription for Seroquel. I was taking Seroquel for the treatment of depression for two years, and I took a drug called Quetiapine. On this occasion, I was taking Seroquel for the treatment of depression for two months, and I was experiencing side effects such as my mood swings and anxiety that I had not noticed before.
The reason I wanted to be a patient with Seroquel was because I needed to see a psychiatrist. I also wanted to see a psychiatrist to see if I was in a good enough mental state to use Seroquel for the treatment of my depression. So, I went to see a psychiatrist. They were very understanding and helpful. I was prescribed Seroquel for the treatment of my depression and I was told that I could stop taking Seroquel on the day my depression was at the highest levels and that it was the best thing that could happen. I was told that this was the only option that was safe for me and that I could stop taking Seroquel and get help.
In the next few months, I was on Seroquel for six months. I was also on an anti-depressant called Zyban. I was told that this drug was to help me reduce my symptoms of depression. I was on a daily medication called Quetiapine, and I was told that this was the only option for me that could help me reduce the symptoms of depression.
I was told that I could stop taking Seroquel on the day my depression was at the highest levels and that it was the best thing that could happen.
I went to see my psychiatrist again the next day. He was very understanding and helpful. I was on Quetiapine for the first time in a few months. I was able to stop taking Seroquel on the day my depression was at the highest levels and that was the best thing that could happen. I was able to get help for the first time in three months. I also was able to get help for the first time in two months.
The next two weeks were difficult, but I felt that I was on Seroquel for the first time in a month. I was in a good mood, but I felt very depressed. I felt very depressed. I was so depressed. I was depressed that I could not sleep at night, and I was unable to function at work or school. I was very anxious. I was depressed that I couldn’t sleep at all. I felt very confused and depressed. I had a lot of anxiety, and I felt very depressed. I was very agitated. I thought that I was going to die. I had no idea that I had done this.
I did not know that I could stop taking Seroquel until I was able to stop taking Seroquel. I was unable to stop taking Seroquel. I was able to stop taking Seroquel.
I was so depressed that I could not function at work or school, and I was unable to work at all. I was so depressed that I could not function at work or school. I was so depressed that I couldn’t work at all. I was so depressed that I could not drive. I was depressed that I couldn’t drive. I was depressed that I couldn’t work at work or school. I was depressed that I couldn’t work at all.
The FDA is warning consumers not to purchase this product as it may cause a serious health problem. The warning is based on information from the.
The U. S. Food and Drug Administration (FDA) has received reports of serious adverse events associated with use of the SEROQUEL XR 10 mg Tablets.
The FDA issued a “black box warning” from October 20, 2017, in the.
A number of safety concerns were identified as contributing to reports of serious adverse events including:
In addition, several drug interactions have been identified, including:
The FDA has also identified an increased risk of serious adverse events in patients taking SEROQUEL XR 10 mg tablets, especially for patients taking atorvastatin. The increased risk of serious adverse events was consistent with increased use. It is possible that these adverse events may have occurred more than once in the individual patient, and that there could have been more than one possible explanation for the increased risk.
Additionally, the FDA has identified a decrease in the ability of SEROQUEL XR 10 mg Tablets to decrease the levels of thyroid-stimulating hormone (TSH) and adrenocorticotropic hormone (ACTH).
A recent study by the American College of Cardiology and the American Heart Association (ACC/AHA) demonstrated that use of SEROQUEL XR 10 mg tablets increased the risk of fatal and non-fatal cardiovascular events in patients with pre-existing conditions.
The FDA has issued a warning from the, which warns patients that they may have a higher risk of serious adverse events if they take SEROQUEL XR 10 mg tablets.
This warning applies to SEROQUEL XR 10 mg Tablets and is based on information from the
and
.
The FDA has also issued a “black box warning” from, which warns patients not to purchase any of the following SEROQUEL XR Tablets, as it can cause a serious health problem:
The FDA has also issued an advisory to be sent to all consumers about SEROQUEL XR 10 mg Tablets that are purchased in the retail store. The FDA warns consumers about SEROQUEL XR 10 mg Tablets that are only available through a prescription.
These safety concerns were identified as contributing to reports of serious adverse events associated with use of the SEROQUEL XR 10 mg Tablets.
A number of other safety concerns were identified as contributing to reports of serious adverse events including:
Additionally, the FDA has issued a warning from the that the increased risk of serious adverse events in patients taking SEROQUEL XR 10 mg Tablets is not consistent with the increased risk observed in patients taking other medications.
These safety concerns were identified as contributing to reports of serious adverse events including:
Atypical antipsychotics are an FDA-approved class of drugs that work by decreasing dopamine activity in the brain. These drugs are often prescribed off-label for mental health conditions. Here’s how they work.
Atypical antipsychotics have been known to treat:
Atypical antipsychotics are available in several forms, including:
Atypical antipsychotics can be effective for:
The mechanism of action for these drugs involves the inhibition of dopamine receptors in the brain. The dopamine and serotonin levels in the brain are regulated by the balance of two key chemicals: Dopamine and Serotonin.
Dopamine is a neurotransmitter involved in the transmission of signals from the central nervous system to the brain. It is involved in controlling the activity of neurons that transmit signals between brain cells.
Serotonin is a chemical that is a neurotransmitter that helps regulate mood. It also plays a role in regulating the activity of other chemicals in the brain. These effects can be particularly important for those who are diagnosed with mood disorders.
Seroquel works by blocking the action of dopamine and serotonin receptors, making these two chemicals less effective in managing symptoms of mood disorders. Seroquel is used in both bipolar and depression.
Atypical antipsychotics may be effective in managing certain mood disorders, although their effectiveness is often not fully studied. It is important to use them under the guidance of a healthcare professional, as some medications may interact with other medications and cause adverse effects. It is also important to understand that the effectiveness of antipsychotics in treating mood disorders may not be fully realized until a more thorough understanding of the mechanisms and potential side effects of these medications is gained.
Stade de France Pharmacy